Navigation Links
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Date:3/27/2008

d therapies.

TRU-015 for RA

In addition to SBI-087, Trubion also announced today the protocol details and design of the next Phase 2b study of TRU-015 for patients with RA that Trubion believes could be supportive of a registration package. The randomized, parallel, double-blind, placebo-controlled, dose regimen-finding study will evaluate the safety and efficacy of two dosing regimens administered to approximately 216 patients with active seropositive RA on a background of methotrexate. The primary outcome measurement for the TRU-015 Phase 2b study will include the American College of Rheumatology (ACR) 50 response measured at 24 weeks. Secondary outcome measurements will be ACR 20 and 70 and DAS-28 responses. This study is currently preparing for participant recruitment.

"SBI-087 strengthens our product pipeline and leverages the combined clinical experience of our strategic collaboration with Wyeth," added Dr. Thompson. "We believe that SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory diseases."

TRU-015 and SBI-087 for SLE

Wyeth intends to pursue clinical evaluation of SBI-087 in Systemic Lupus Erythematosus (SLE) and an investigational new drug filing is expected by the end of the year. As a result, Wyeth no longer intends to evaluate TRU-015 in a planned Phase 1 study originally designed to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus. No patients were enrolled in the planned TRU-015 Phase 1 study.

TRU-015 for NHL

Trubion also announced today that Wyeth, in reviewing the competitive landscape for CD20-directed therapies, has determined not to pursue such therapies for oncology indications and, as a result, has discontinued clinical development of TRU-015 for non-Hodgkin's lymphoma.

In addition to TRU-015 and SBI-0
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
5. Metabolex Initiates Phase 1 Trial of MBX-2982
6. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
9. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
10. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... study comparing the novel investigational drug axomadol against placebo in ... back pain. The results indicate that axomadol did not meet ... analyses of the data and evaluating the path forward for ...
... 30, 2011 UCB and Harvard University officially launched ... took place in Boston last night in the presence ... (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) The ... and academia, with Harvard scientists continuing their research that ...
Cached Medicine Technology:Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
(Date:7/10/2014)... (HealthDay News) -- Most professional football players who have ... game, a new study finds. Shoulder instability is ... of return after surgery to fix the problem has ... study included 60 players who had shoulder stabilization surgery. ... returned to play, defined as playing in at least ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... of 10 adults make use of calorie information on menus, ... according to a new U.S. study. Women in particular ... Hee Lee-Kwan, an epidemiologist with the U.S. Centers for Disease ... they used menu labeling to help choose their meal, compared ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
(Date:7/10/2014)... the top public health concerns in the United States, ... obese as of 2012. As health problems such as ... Twitter to discuss the problem. , A new study, ... the Brown School at Washington University in St. Louis, ... to track Twitter conversations about the issue of overweight ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:Study looks at how Twitter can be used to address specific health issues 2
... data from Understanding Society based on 14,000 UK households found ... higher levels of education and by married people. The ... with those in routine occupations reporting worse sleep than those ... University of Surrey who analysed the findings said: "Given the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- ... seven hours a night, which affects their concentration and ... also impairs work performance and the ability to drive ... Control and Prevention (CDC), which published two sleep studies ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... An analysis of breast tissue may help doctors better predict ... Researchers analyzed what they describe as "highways" of connective ... collagen fibers -- the main component of connective tissue -- ... determine treatment. Collagen not only surrounds most body organs ...
... -- New findings about brain rhythms could lead to the ... A team at Massachusetts General Hospital found that a brain ... hidden form during sleep, where it becomes more intense at ... to being awakened by noise or other disturbances. To ...
... The burning, tingling pain of neuropathy may affect feet ... of nerve cells that supply the extremities age and ... these areas, Johns Hopkins scientists suggest in a new ... to fight neuropathy, a condition that often accompanies other ...
Cached Medicine News:Health News:The better off sleep better 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Breast cancer survivors at higher risk for falls 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 3
ELISA kit for CMV CAP M....
Cytomegalovirus IgG ELISA....
Cytomegalovirus IgM ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Medicine Products: